Boston Scientific Begins U.S. and International Launch of Expect(TM) Endoscopic Ultrasound Aspiration Needle

By Boston Scientific Corporation, PRNE
Sunday, May 8, 2011

Innovative Fine Needle Aspiration Technology Expands Diagnostic Capabilities in Pancreas and Gastrointestinal Tract

NATICK, Massachusetts, May 9, 2011 - Boston Scientific Corporation (NYSE: BSX) today announced the
U.S. and international launch of its Expect(TM) Endoscopic Ultrasound
Aspiration Needle, used for acquiring tissue samples for diagnosing and
staging malignancies in organs adjacent to the gastrointestinal tract. The
Expect Needle received FDA clearance and CE Mark approval earlier this year
and is being marketed in the U.S., Europe and other international markets.

Endoscopic ultrasound (EUS) is a non-surgical, less-invasive
procedure that uses high-frequency sound waves to produce detailed images of
the gastrointestinal tract and adjacent organs, including the pancreas,
liver, bile duct and mediastinal space. To complement EUS, Fine Needle
Aspiration (FNA) is often used to collect cytology samples for cancer
diagnosis. Data have shown that EUS is associated with improved survival
rates for pancreatic cancer patients due to more informed, stage-appropriate
disease management[1].

"Combining EUS with FNA offers powerful diagnostic
capabilities that can help optimize malignancy management in the GI tract and
inform appropriate treatment paths for the patient, including surgery,
chemotherapy, radiation or palliation," said Robert H. Hawes, M.D., Professor
of Medicine, Division of Gastroenterology and Hepatology, at the Medical
University of South Carolina
in Charleston. "The excellent visibility,
sharpness and durability of the Expect Needle help obtain high-quality
diagnostic samples easily and efficiently."

The Expect Needle features an echogenic pattern providing
excellent visibility and precise needle guidance within the targeted organ or
structure. The cobalt chromium design is engineered to offer improved
sharpness and pushability, along with deformation resistance, compared to
traditional stainless steel needles. As a result, physicians may be able to
more easily and accurately obtain a tissue sample while maintaining excellent
visibility during the procedure.

"The quality of tissue samples is critical to accurately
assessing malignancies, which in turn impact treatment algorithms," said
Shyam Varadarajulu, M.D., Director of Endoscopy, University of Alabama,
. "The Expect Needle yields detailed, high-quality samples that
enable rapid evaluation of lesions and abnormalities to determine the
specific stage of malignancies."

"The launch of the Expect Needle broadens our Endoscopy
portfolio and further strengthens our leadership position in
pancreaticobiliary disease management," said David Pierce, President of
Boston Scientific's Endoscopy Division. "Providing physicians with an
innovative, durable aspiration needle for EUS-FNA procedures highlights our
commitment to delivering a full suite of advanced technologies to diagnose
gastrointestinal diseases and help improve patient care."

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and
marketer of medical devices whose products are used in a broad range of
interventional medical specialties. For more information, please visit:

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Forward-looking statements may be identified
by words like "anticipate," "expect," "project," "believe," "plan,"
"estimate," "intend" and similar words. These forward-looking statements are
based on our beliefs, assumptions and estimates using information available
to us at the time and are not intended to be guarantees of future events or
performance. These forward-looking statements include, among other things,
statements regarding our business plans, the pancreaticobiliary disease
management market and our share of that market, new product launches and
launch cadence, regulatory approvals, clinical trials, studies, product
performance and competitive offerings. If our underlying assumptions turn out
to be incorrect, or if certain risks or uncertainties materialize, actual
results could vary materially from the expectations and projections expressed
or implied by our forward-looking statements. These factors, in some cases,
have affected and in the future (together with other factors) could affect
our ability to implement our business strategy and may cause actual results
to differ materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place undue
reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; new product performance; demographic trends;
intellectual property; litigation; financial market conditions; and future
business decisions made by us and our competitors. All of these factors are
difficult or impossible to predict accurately and many of them are beyond our
control. For a further list and description of these and other important
risks and uncertainties that may affect our future operations, see Part I,
Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed
with the Securities and Exchange Commission, which we may update in Part II,
Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or
will file hereafter. We disclaim any intention or obligation to publicly
update or revise any forward-looking statements to reflect any change in our
expectations or in events, conditions or circumstances on which those
expectations may be based, or that may affect the likelihood that actual
results will differ from those contained in the forward-looking statements.
This cautionary statement is applicable to all forward-looking statements
contained in this document.


[1] Ngamruengphong, et al. "EUS and survival in patients with pancreatic
cancer: a population-based study," Gastrointestinal Endoscopy, 2010. 72 (1)


    Erik Kopp
    508-650-8660 (office)
    Media Relations
    Boston Scientific Corporation

    Sean Wirtjes
    508-652-5305 (office)
    Investor Relations
    Boston Scientific Corporation


will not be displayed